Gemcabene

DB05123InvestigationalSmall molecule

Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C).

Chemical structure of Gemcabene
Primary indication
Investigated for use/treatment in atherosclerosis, cardiovascular disorders, and hyperlipidemia.Curator reviewed
Formula / weight
C16H30O5 · 302.4064 g/mol (avg)

Resolves to

Compound
UNIIB96UX1DDKSCAS183293-82-5ChEMBLCHEMBL2110686PubChem157692
Structure
InChIKeySDMBRCRVFFHJKR-UHFFFAOYSA-NSMILESCC(C)(CCCCOCCCCC(C)(C)C(O)=O)C(O)=O

What you can answer from here — as of February 21, 2021

9Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Gemcabene, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In